Skip to main content
Erschienen in: Medical Oncology 12/2014

01.12.2014 | Original Paper

Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component

verfasst von: Shinji Matsumoto, Kazuki Nabeshima, Makoto Hamasaki, Tatsuki Shibuta, Tsukuru Umemura

Erschienen in: Medical Oncology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Malignant pleural mesothelioma (MPM) is a neoplastic disease with a poor prognosis. The complete resection of tumor with extra-pleural pneumonectomy is effective only for early stage epithelioid-type MPM. An accurate pathological diagnosis including the histological subtype and also clinical staging are crucial to decide on the therapeutic approach. However, the pathological diagnosis is difficult when the amount of biopsy sample is small. We performed a comparative analysis of the miR-31 expression in MPM and reactive mesothelial proliferations (RMPs), by RT-qPCR of formaldehyde-fixed paraffin-embedded samples, and compared the expression levels of miR-31 with the results of a survival analysis for the diagnosis and prognosis of MPM. The expression of miR-31 was found to be significantly reduced in MPMs compared with RMPs (P < 0.01). The pathological subtype of four among five cases with upregulated miR-31 levels was MPM with a sarcomatoid component. (i.e., biphasic or sarcomatoid type). Furthermore, these four cases were significantly associated with a worse prognosis compared with the five cases of biphasic or sarcomatoid MPM without upregulated miR-31 expression (P = 0.0027). In conclusion, the analysis of miR-31 expression levels may be a good biomarker for diagnosis of MPM histological typing and predicting the prognosis.
Literatur
1.
Zurück zum Zitat Kamp DW. Asbestos-induced lung diseases: an update. Transl Res J Lab Clin Med. 2009;153(4):143–52.CrossRef Kamp DW. Asbestos-induced lung diseases: an update. Transl Res J Lab Clin Med. 2009;153(4):143–52.CrossRef
2.
Zurück zum Zitat Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49(1):1–7.PubMedCrossRef Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49(1):1–7.PubMedCrossRef
3.
Zurück zum Zitat Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081–90.PubMedCrossRef Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27(12):2081–90.PubMedCrossRef
4.
Zurück zum Zitat Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453(6):627–35.PubMedCrossRef Dacic S, Kothmaier H, Land S, Shuai Y, Halbwedl I, Morbini P, et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008;453(6):627–35.PubMedCrossRef
5.
Zurück zum Zitat Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010;138(1):137–44.PubMed Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B, et al. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest. 2010;138(1):137–44.PubMed
6.
Zurück zum Zitat Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619–27.PubMedCrossRef Monaco SE, Shuai Y, Bansal M, Krasinskas AM, Dacic S. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. Am J Clin Pathol. 2011;135(4):619–27.PubMedCrossRef
7.
Zurück zum Zitat Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, et al. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol. 2013;121(8):415–22.PubMedCrossRef Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, et al. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol. 2013;121(8):415–22.PubMedCrossRef
8.
Zurück zum Zitat Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139(1):39–46.PubMedCrossRef Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, et al. Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol. 2013;139(1):39–46.PubMedCrossRef
9.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef
10.
Zurück zum Zitat Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M, et al. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res. 2013;37(10):1278–86.PubMedCrossRef Shibuta T, Honda E, Shiotsu H, Tanaka Y, Vellasamy S, Shiratsuchi M, et al. Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib. Leuk Res. 2013;37(10):1278–86.PubMedCrossRef
11.
Zurück zum Zitat Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348–60.PubMedCentralPubMedCrossRef Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14(11):2348–60.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34(2):219–24.PubMedCrossRef Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck. 2012;34(2):219–24.PubMedCrossRef
13.
Zurück zum Zitat Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120(4):1298–309.PubMedCentralPubMedCrossRef Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010;120(4):1298–309.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72(5–6):397–402.PubMedCrossRef Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72(5–6):397–402.PubMedCrossRef
15.
Zurück zum Zitat Zhang Y, Guo J, Li D, Xiao B, Miao Y, Jiang Z, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol. 2010;27(3):685–9.PubMedCrossRef Zhang Y, Guo J, Li D, Xiao B, Miao Y, Jiang Z, et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance. Med Oncol. 2010;27(3):685–9.PubMedCrossRef
16.
Zurück zum Zitat Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol. 2013;15(10):849–54.PubMedCrossRef Wang S, Li Q, Wang K, Dai Y, Yang J, Xue S, et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol. 2013;15(10):849–54.PubMedCrossRef
17.
Zurück zum Zitat Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12(6):771–9.PubMedCentralPubMedCrossRef Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, et al. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12(6):771–9.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 2011;6(4):e18232.PubMedCentralPubMedCrossRef Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, et al. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One. 2011;6(4):e18232.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25(1):86–99.PubMedCrossRef Fassina A, Cappellesso R, Guzzardo V, Dalla Via L, Piccolo S, Ventura L, et al. Epithelial-mesenchymal transition in malignant mesothelioma. Mod Pathol. 2012;25(1):86–99.PubMedCrossRef
20.
Zurück zum Zitat Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42(3):312–9.PubMedCrossRef Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol. 2010;42(3):312–9.PubMedCrossRef
21.
Zurück zum Zitat Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res. 2011;17(15):4965–74.PubMedCrossRef Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res. 2011;17(15):4965–74.PubMedCrossRef
22.
Zurück zum Zitat Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–35. Reid G, Pel ME, Kirschner MB, Cheng YY, Mugridge N, Weiss J, et al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. Ann Oncol. 2013;24(12):3128–35.
23.
Zurück zum Zitat Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol. 2011;6(5):844–51.PubMedCrossRef Balatti V, Maniero S, Ferracin M, Veronese A, Negrini M, Ferrocci G, et al. MicroRNAs dysregulation in human malignant pleural mesothelioma. J Thorac Oncol. 2011;6(5):844–51.PubMedCrossRef
24.
Zurück zum Zitat Andersen M, Grauslund M, Muhammad-Ali M, Ravn J, Sorensen JB, Andersen CB, et al. Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma? APMIS. 2012;120(9):767–9.PubMedCrossRef Andersen M, Grauslund M, Muhammad-Ali M, Ravn J, Sorensen JB, Andersen CB, et al. Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma? APMIS. 2012;120(9):767–9.PubMedCrossRef
25.
Zurück zum Zitat Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(7):1184–91.PubMedCrossRef Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(7):1184–91.PubMedCrossRef
26.
Zurück zum Zitat Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809–17.PubMedCentralPubMedCrossRef Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285(30):22809–17.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Travis WD, Muller-Hermelink HK, World Health Organization Classification of Tumours. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer Press; 2004. Travis WD, Muller-Hermelink HK, World Health Organization Classification of Tumours. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: International Agency for Research on Cancer Press; 2004.
28.
Zurück zum Zitat Masaki S, Ohtsuka R, Abe Y, Muta K, Umemura T. Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun. 2007;364(3):509–14.PubMedCrossRef Masaki S, Ohtsuka R, Abe Y, Muta K, Umemura T. Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem Biophys Res Commun. 2007;364(3):509–14.PubMedCrossRef
29.
Zurück zum Zitat Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227–31.PubMed Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995;55(6):1227–31.PubMed
30.
Zurück zum Zitat Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71(3):873–83.PubMedCrossRef Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71(3):873–83.PubMedCrossRef
31.
Zurück zum Zitat Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004;16(4):415–21.PubMedCrossRef Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004;16(4):415–21.PubMedCrossRef
32.
Zurück zum Zitat Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012;2(12):1100–8.PubMedCentralPubMedCrossRef Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012;2(12):1100–8.PubMedCentralPubMedCrossRef
Metadaten
Titel
Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component
verfasst von
Shinji Matsumoto
Kazuki Nabeshima
Makoto Hamasaki
Tatsuki Shibuta
Tsukuru Umemura
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 12/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0303-2

Weitere Artikel der Ausgabe 12/2014

Medical Oncology 12/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.